Drug intelligence / Profile preview

NuQu

Development stage: Unknown
Lead developer: ISTO Biologics
Modality: Cell Therapies
Administration: Intradiscal

Overview

NuQu is a cell-based therapy developed by ISTO Technologies for the treatment of painful spinal disc conditions. It was investigated in clinical trials as a novel regenerative approach targeting intervertebral disc degeneration, aiming to alleviate pain and restore function. The therapy involves the injection of cells into degenerated spinal discs to promote tissue repair and regeneration. NuQu is not an approved pharmaceutical product; it has been studied in clinical trials for spine-related indications but does not have established regulatory approval or widespread commercial availability.

Brand names: NuQu

Beyond the preview

Go deeper on NuQu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NuQu.

Explore the full profile